The DOI matches its Crossref record.
Gabapentin (Neurontin) as Add‐on Therapy in Patients with Partial Seizures: A Double‐Blind, Placebo‐Controlled Study
Abstract
Summary: A multicenter, double‐blind, randomized, placebo‐controlled study evaluated the efficacy and safety of gabapentin (Neurontin, GBP) as add‐on therapy in 272 patients with refractory partial seizures who were receiving one to two standard antiepileptic drugs (AEDs). Efficacy assessments compared the frequency of partial seizures during the 12‐week treatment phase (T) and the 12‐week baseline period (B). The primary analysis compared data for patients receiving GBP 900 mg/day with placebo; the GBP 1,200‐mglday group provided doseresponse data. Efficacy criteria were percentage of change in seizure frequency (PCH), responder rate (percentage of patients with ≥50% reduction in seizure frequency), and response ratio, where RRatio = (T B)/(T + B). Median PCH was–21.8% in the 900‐mg/day group and −17.8% in the 1,200‐mg/day group as compared with −0.3% in the placebo group. Responder rate was 22.9% in the 900‐mg/day group and 10.1% in the placebo group (p = 0.020, Fisher's exact test). Adjusted mean Rratio was‐0.136 in the 900‐mg/day group and −0.025 in the placebo group (p = 0.0046, analysis of variance ANOVA). Results showed slightly greater improvement for the 1,20‐mg/day than for the 900‐mg/day group (RRatio =−0.157, responder rate 28.0%). Adverse events (AE) occurred in 69% of patients in the 900‐mg/day group and in 64% in the 1,200‐mg/day group as compared with 52% in patients receiving placebo as add‐on therapy. The most frequent AE among patients treated with GBP were somnolence, dizziness, and fatigue. Clinical laboratory evaluations showed no clinically important trends and no evidence of hepatic or hematopoietic effects. GBP is safe and effective in treating some patients with refractory partial seizures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Antiepileptic Drugs as a Cause of Worsening Seizures
Perucca, E., Gram, L., Avanzini, G., & Dulac, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01268.x · Cited by 543
Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467
The Expert Consensus Guideline Series
Karceski, S., Morrell, M., & Carpenter, D. (2001) · Epilepsy & Behavior · doi:10.1006/ebeh.2001.0283 · Cited by 396
The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability
Marson, A. G., Kadir, Z. A., Hutton, J. L., & Chadwick, D. W. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01251.x · Cited by 347
Metadata
- Authors
- Anhut, H., Ashman, P., Feuerstein, T. J., Sauermann, W., Saunders, M., Schmidt, B., & The International Gabapentin Study Group
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 1994-07
- Volume
- 35
- Issue
- 4
- Pages
- 795-801
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1995716893
- Cited by
- 190
- References
- 0
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gabapentin (Neurontin) as Add‐on Therapy in Patients with Partial Seizures: A Double‐Blind, Placebo‐Controlled Study. https://app.cochat.ai/papers/10.1111/j.1528-1157.1994.tb02513.x
- The paper
- Anhut, H., Ashman, P., Feuerstein, T. J., Sauermann, W., Saunders, M., Schmidt, B., & The International Gabapentin Study Group. (1994). Gabapentin (Neurontin) as Add‐on Therapy in Patients with Partial Seizures: A Double‐Blind, Placebo‐Controlled Study. Epilepsia. https://doi.org/10.1111/j.1528-1157.1994.tb02513.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.